In addition, Han et al. [37] demonstrated that Korean patients with non-small-cell lung cancer who had the UGT1A1*6/*6 genotype and were treated with irinotecan and cisplatin experienced reduced tumor response rates, along with shorter progression-free survival and overall survival, compared to patients with other genotypes. This evidence concerns the gene UGT1A1 and neoplasm.